Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3194541 | 1.00 | MAPT (0.52) | MAPTPKMSLC6A2SLC6A4SLC18A2 | |
| SCHEMBL3204850 | 1.00 | MAPT (0.52) | MAPTPKMSLC6A2SLC6A4SLC18A2 | |
| SCHEMBL3194554 | 1.00 | MAPT (0.52) | MAPTPKMSLC6A2SLC6A4SLC18A2 | |
| SCHEMBL3204864 | 1.00 | MAPT (0.52) | MAPTPKMSLC6A2SLC6A4SLC18A2 | |
| SCHEMBL2187901 | 0.92 | MAPT (0.60) | MAPTPKMSLC18A2TSHRL3MBTL1 | |
| SCHEMBL2188641 | 0.92 | MAPT (0.60) | MAPTPKMSLC18A2TSHRL3MBTL1 | |
| SCHEMBL2187908 | 0.92 | MAPT (0.60) | MAPTPKMSLC18A2TSHRL3MBTL1 | |
| SCHEMBL2187910 | 0.92 | MAPT (0.60) | MAPTPKMSLC18A2TSHRL3MBTL1 | |
| SCHEMBL2188645 | 0.92 | MAPT (0.60) | MAPTPKMSLC18A2TSHRL3MBTL1 | |
| SCHEMBL2188619 | 0.85 | MAPT (0.45) | MAPTPKMSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035865-A1 | Sulfonamides and Pharmaceutical Compositions Thereof | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| EP-2142505-A1 | SULFONAMIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF | Pfizer, Inc. (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008120093-A1 | SULFONAMIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035865-A1 | Sulfonamides and Pharmaceutical Compositions Thereof | STS, SULT2A1, SULT1A1 | MAPT 3002/4885PKM 1812/4885SLC6A2 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.